Sugi Predict

Sugi Predict / Compounds / SCHEMBL62508

SCHEMBL62508

SCHEMBL62508

CC(C)(C)OC(=O)N1CCC(C(=O)OCCl)CC1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.57
▸ RECQL P46063 1/20 0.55
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ PTPN2 P17706 1/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ PTPN6 P29350 1/20 0.50
▸ EPHX1 P07099 1/20 0.48
▸ STS P08842 5/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAPT P10636 2/20 0.45
▸ GPR119 Q8TDV5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337418 0.88 ALDH1A1 (0.65) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL61303 0.86 HPGD (0.56) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL11904378 0.85 HPGD (0.66) HPGDRECQLKMT2APTPN2PTPN1
SCHEMBL28814029 0.85 HPGD (0.55) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL22504762 0.85 HPGD (0.55) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL23173139 0.85 HPGD (0.55) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL28730455 0.85 HPGD (0.55) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL19772544 0.85 HPGD (0.55) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL25736762 0.85 HPGD (0.55) HPGDRECQLKMT2AMEN1ALDH1A1
SCHEMBL28730457 0.84 HPGD (0.54) HPGDRECQLKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507760-B1 CYANOGUANIDINE PRODRUGS LEO PHARMA AS (DK) 2007-08-01 — — EP claimed
EP-0968206-B8 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX INC (US) 2007-01-24 — — EP claimed
US-20050215588-A1 Cyanoguanidine prodrugs LEO PHARMA A/S (DK) 2005-09-29 — — US claimed
CN-1662501-A Cyanoguanidine prodrugs LEO PHARMA AS (DK) 2005-08-31 — — CN claimed
EP-0968206-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 2000-01-05 — — EP claimed
WO-1998037079-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS BERLEX LABORATORIES, INC. (US) 1998-08-27 — — WO claimed
EP-4630415-A1 TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN Captor Therapeutics S.A. (PL) 2025-10-15 — — EP disclosed
WO-2024121259-A1 TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-06-13 — — WO disclosed
WO-2024123195-A1 TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-06-13 — — WO disclosed
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-12-07 — — US disclosed
EP-3094630-B1 READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS UNIV CALIFORNIA (US) 2021-10-20 — — EP disclosed
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2020-02-27 — — US disclosed
US-10287283-B2 Read-through compound prodrugs suppressing premature nonsense mutations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-05-14 — — US disclosed
US-7253193-B2 Cyanoguanidine prodrugs LEO PHARMA A/S (DK) 2007-08-07 — — US disclosed
EP-1507760-B1 CYANOGUANIDINE PRODRUGS LEO PHARMA AS (DK) 2007-08-01 — — EP disclosed
EP-1556391-B1 LIPID-ANALOG PHOSPHORIC ACID TRIESTER MAX PLANCK GESELLSCHAFT (DE) 2007-08-01 — — EP disclosed
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-11-23 — — US disclosed
WO-2006114093-A1 PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-11-02 — — WO disclosed
US-20050215588-A1 Cyanoguanidine prodrugs LEO PHARMA A/S (DK) 2005-09-29 — — US disclosed
CN-1662501-A Cyanoguanidine prodrugs LEO PHARMA AS (DK) 2005-08-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF CRBN, PDCD11, CD47 HPGD 3193/4885RECQL 3770/4885KMT2A 2200/4885
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof CRBN, PDCD11, CD47 HPGD 2771/4885RECQL 3902/4885KMT2A 2282/4885
US-20060264485-A1 Pro-drugs of N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA2B, ADORA1 HPGD 2461/4885RECQL 2774/4885KMT2A 2807/4885
US-10287283-B2 Read-through compound prodrugs suppressing premature nonsense mutations UPF1, NUDT21, RNMT HPGD 3102/4885RECQL 1619/4885KMT2A 1096/4885
US-20050215588-A1 Cyanoguanidine prodrugs CCNT1, CCND2, CCNT2 HPGD 115/4885RECQL 733/4885KMT2A 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.